NCT06048718 - T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

July 31, 2026

Conditions

Breast CancerMetastatic Breast Cancer

Interventions

DRUG

Trastuzumab-Deruxtecan (T-DXd)

Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.

Trial Locations (13)

1090

RECRUITING

Medical University of Vienna, Vienna

14004

RECRUITING

Hospital Universitario Reina Sofía, Córdoba

18016

RECRUITING

Hospital Universitario Clínico San Cecilio de Granada, Granada

28007

RECRUITING

Hospital Beata María Ana, Madrid

28034

RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

41013

RECRUITING

Hospital Universitario Virgen del Rocío, Seville

46010

RECRUITING

Hospital Clínico Universitario de Valencia, Valencia

46015

RECRUITING

Hospital Arnau de Vilanova de Valencia, Valencia

48013

RECRUITING

Hospital Universitario de Basurto, Bilbao

Unknown

RECRUITING

Salzburg Cancer research Institute-Center, Salzburg

03550

RECRUITING

Hospital Universitario San Juan de Alicante, Alicante

08028

RECRUITING

Hospital Universitari Dexeus, Barcelona

08035

RECRUITING

Hospital Universitari Vall D'Hebron, Barcelona